305 related articles for article (PubMed ID: 25723399)
1. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.
Qu D; Johnson J; Chandrakesan P; Weygant N; May R; Aiello N; Rhim A; Zhao L; Zheng W; Lightfoot S; Pant S; Irvan J; Postier R; Hocker J; Hanas JS; Ali N; Sureban SM; An G; Schlosser MJ; Stanger B; Houchen CW
PLoS One; 2015; 10(2):e0118933. PubMed ID: 25723399
[TBL] [Abstract][Full Text] [Related]
2. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
[TBL] [Abstract][Full Text] [Related]
3. The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.
Dandawate P; Ghosh C; Palaniyandi K; Paul S; Rawal S; Pradhan R; Sayed AAA; Choudhury S; Standing D; Subramaniam D; Padhye SB; Gunewardena S; Thomas SM; Neil MO; Tawfik O; Welch DR; Jensen RA; Maliski S; Weir S; Iwakuma T; Anant S; Dhar A
Gastroenterology; 2019 Dec; 157(6):1646-1659.e11. PubMed ID: 31442435
[TBL] [Abstract][Full Text] [Related]
4. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells.
Zhang Y; Zoltan M; Riquelme E; Xu H; Sahin I; Castro-Pando S; Montiel MF; Chang K; Jiang Z; Ling J; Gupta S; Horne W; Pruski M; Wang H; Sun SC; Lozano G; Chiao P; Maitra A; Leach SD; Kolls JK; Vilar E; Wang TC; Bailey JM; McAllister F
Gastroenterology; 2018 Jul; 155(1):210-223.e3. PubMed ID: 29604293
[TBL] [Abstract][Full Text] [Related]
5. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
6. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer.
Bailey JM; Alsina J; Rasheed ZA; McAllister FM; Fu YY; Plentz R; Zhang H; Pasricha PJ; Bardeesy N; Matsui W; Maitra A; Leach SD
Gastroenterology; 2014 Jan; 146(1):245-56. PubMed ID: 24096005
[TBL] [Abstract][Full Text] [Related]
7. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer.
Sureban SM; May R; Qu D; Weygant N; Chandrakesan P; Ali N; Lightfoot SA; Pantazis P; Rao CV; Postier RG; Houchen CW
PLoS One; 2013; 8(9):e73940. PubMed ID: 24040120
[TBL] [Abstract][Full Text] [Related]
8. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization.
Chandrakesan P; Panneerselvam J; May R; Weygant N; Qu D; Berry WR; Pitts K; Stanger BZ; Rao CV; Bronze MS; Houchen CW
Mol Cancer Ther; 2020 Jul; 19(7):1539-1549. PubMed ID: 32371580
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
[TBL] [Abstract][Full Text] [Related]
10. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
[TBL] [Abstract][Full Text] [Related]
11. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
Sureban SM; Madhoun MF; May R; Qu D; Ali N; Fazili J; Weygant N; Chandrakesan P; Ding K; Lightfoot SA; Houchen CW
Oncotarget; 2015 Nov; 6(35):37200-15. PubMed ID: 26468984
[TBL] [Abstract][Full Text] [Related]
12. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.
Whorton J; Sureban SM; May R; Qu D; Lightfoot SA; Madhoun M; Johnson M; Tierney WM; Maple JT; Vega KJ; Houchen CW
Dig Dis Sci; 2015 Feb; 60(2):509-13. PubMed ID: 25283374
[TBL] [Abstract][Full Text] [Related]
13. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.
Yan R; Li J; Zhou Y; Yao L; Sun R; Xu Y; Ge Y; An G
Life Sci; 2020 Jan; 241():117150. PubMed ID: 31837335
[TBL] [Abstract][Full Text] [Related]
15. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
Tao H; Tanaka T; Okabe K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1449-1459. PubMed ID: 28382517
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-195 Suppresses the Progression of Pancreatic Cancer by Targeting DCLK1.
Zhou B; Sun C; Hu X; Zhan H; Zou H; Feng Y; Qiu F; Zhang S; Wu L; Zhang B
Cell Physiol Biochem; 2017; 44(5):1867-1881. PubMed ID: 29224010
[TBL] [Abstract][Full Text] [Related]
17. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.
Sureban SM; May R; Weygant N; Qu D; Chandrakesan P; Bannerman-Menson E; Ali N; Pantazis P; Westphalen CB; Wang TC; Houchen CW
Cancer Lett; 2014 Aug; 351(1):151-61. PubMed ID: 24880079
[TBL] [Abstract][Full Text] [Related]
18. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging.
Maruno T; Fukuda A; Goto N; Tsuda M; Ikuta K; Hiramatsu Y; Ogawa S; Nakanishi Y; Yamaga Y; Yoshioka T; Takaori K; Uemoto S; Saur D; Chiba T; Seno H
Elife; 2021 Jan; 10():. PubMed ID: 33393460
[TBL] [Abstract][Full Text] [Related]
19. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients.
Mirzaei A; Tavoosidana G; Modarressi MH; Rad AA; Fazeli MS; Shirkoohi R; Tavakoli-Yaraki M; Madjd Z
Tumour Biol; 2015 Jun; 36(6):4801-10. PubMed ID: 25631749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
